BriaCell Presents Clinical Efficacy Data Of Randomized Phase 2 Study Evaluating Bria-IMT In Patients With Advanced Metastatic Breast Cancer At ASCO 2024

6/3/24 8:29:16 AM ET

$BCTX

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $BCTX alert in real time by email

BriaCell doubles Progression-Free-Survival (PFS) and Clinical Benefit Rate vs historical results in the literature
Bria-IMT™ PFS compares favorably to PFS of most recent treatment in 48% of Antibody-Drug Conjugate (ADC) resistant patients
Therapy well-tolerated with no Bria-IMT™ related discontinuations
Clinical data highlight significant potential of Bria-IMT™ in advanced metastatic breast cancer
Superiority of selected Phase 3 regimen and formulation confirmed
Oral presentation by Mayo Clinic Professor and Principal Investigator, Saranya Chumsri, MD, on Monday June 3; 11:30 AM-1:00 PM CDT

Get the next $BCTX alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$BCTX

Date	Price Target	Rating	Analyst
2/14/2022	$25.00	Buy	HC Wainwright & Co.

More analyst ratings

BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting
PHILADELPHIA, Pa. and VANCOUVER, British Columbia, Feb. 05, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce the results of its annual general meeting of shareholders of the Company (the "Shareholders") for the year ended July 31, 2024 held on February 5, 2025 (the "Meeting"). A total of 36.26% of the Company's issued and outstanding common shares (the "Common Shares") were voted at the Meeting. At the Meeting, the Shareholders overwhelmingly voted in favour of all proposed resolutions, consisting of
2/5/25 6:15:47 PM ET
$BCTX
Biotechnology: Pharmaceutical Preparations
Health Care
BriaCell Announces Rescheduling of its Annual General Meeting of Shareholders to February 5, 2025
PHILADELPHIA and VANCOUVER, British Columbia, Jan. 03, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces that the Company's Annual General Meeting of Shareholders (the "Meeting"), which was originally scheduled to be held on Thursday, January 23, 2025, has been rescheduled. The Meeting is now scheduled to be held on Wednesday, February 5, 2025, at 9:00 a.m. (ET) at Suite 3400, One First Canadian Place, Toronto, ON, M5X 1A4. The record date for the Meeting, December 9, 2024, is unchanged and applies to the postponed
1/3/25 5:05:00 PM ET
$BCTX
Biotechnology: Pharmaceutical Preparations
Health Care
BriaCell Announces Availability of Annual General Meeting Materials and Alternative Voting Procedures
PHILADELPHIA and VANCOUVER, British Columbia, Dec. 17, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces that the Company will be relying on, and has satisfied all of the conditions to rely on, CSA Coordinated Blanket Order 51-931 for exemption from the requirements to send proxy-related materials (the "Meeting Materials") for its upcoming annual general meeting (the "Meeting") to be held on Thursday, January 23, 2025, at Suite 3400, One First Canadian Place, Toronto, ON, M5X 1A4. at 10:00 a.m. (EST) due to the susp
12/17/24 4:05:59 PM ET
$BCTX
Biotechnology: Pharmaceutical Preparations
Health Care

$BCTX
Press Releases

Fastest customizable press release news feed in the world

BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting
PHILADELPHIA, Pa. and VANCOUVER, British Columbia, Feb. 05, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce the results of its annual general meeting of shareholders of the Company (the "Shareholders") for the year ended July 31, 2024 held on February 5, 2025 (the "Meeting"). A total of 36.26% of the Company's issued and outstanding common shares (the "Common Shares") were voted at the Meeting. At the Meeting, the Shareholders overwhelmingly voted in favour of all proposed resolutions, consisting of
2/5/25 6:15:47 PM ET
$BCTX
Biotechnology: Pharmaceutical Preparations
Health Care
BriaCell Therapeutics Announces Closing of Public Offering
PHILADELPHIA and VANCOUVER, British Columbia, Feb. 05, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announced the closing of its previously announced best-efforts public offering of 762,500 common shares at a public offering price of $4.00 per share. The Company received gross proceeds from the offering, before deducting the placement agent's fees and other offering expenses, of $3.05 million. The Company relied upon the exemption set forth in Section 602.1 of the TSX Company Manual, which provides that the TSX wil
2/5/25 4:05:28 PM ET
$BCTX
Biotechnology: Pharmaceutical Preparations
Health Care
BriaCell Therapeutics Announces Pricing of Public Offering
PHILADELPHIA and VANCOUVER, British Columbia, Feb. 03, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announced the pricing of a best-efforts public offering of 762,500 common shares at a public offering price of $4.00 per share. Total gross proceeds from the offering, before deducting placement agent fees and other offering expenses, are expected to be $3.05 million. The offering is expected to close on February 5, 2025, subject to satisfaction of customary closing conditions. The Company is relying upon the exempti
2/3/25 7:59:28 PM ET
$BCTX
Biotechnology: Pharmaceutical Preparations
Health Care

BriaCell Presents Clinical Efficacy Data Of Randomized Phase 2 Study Evaluating Bria-IMT In Patients With Advanced Metastatic Breast Cancer At ASCO 2024

Chat with this insight

Recent Analyst Ratings for
$BCTX

$BCTX
Financials

Live finance-specific insights

ImmunoPrecise Reports Financial Results and Recent Business Highlights for Full Fiscal Year 2023

$BCTX
Leadership Updates

Live Leadership Updates

BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting

BriaCell Announces Rescheduling of its Annual General Meeting of Shareholders to February 5, 2025

BriaCell Announces Availability of Annual General Meeting Materials and Alternative Voting Procedures

$BCTX
Press Releases

Fastest customizable press release news feed in the world

BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting

BriaCell Therapeutics Announces Closing of Public Offering

BriaCell Therapeutics Announces Pricing of Public Offering

$BCTX
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Lustig Marc bought $2,000,001 worth of shares (902,935 units at $2.21) (SEC Form 4)

$BCTX
SEC Filings

BriaCell Therapeutics Corp. filed SEC Form 8-K: Other Events

BriaCell Therapeutics Corp. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

BriaCell Therapeutics Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits

$BCTX
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Lustig Marc bought $2,000,001 worth of shares (902,935 units at $2.21) (SEC Form 4)

SEC Form 4: Bondarenko Jamieson bought $128,240 worth of shares (28,000 units at $4.58), increasing direct ownership by 20% to 169,856 units

SEC Form 4 filed by Williams William V.

$BCTX
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

HC Wainwright & Co. initiated coverage on BriaCell Therapeutics with a new price target

$BCTX
Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13D/A filed by BriaCell Therapeutics Corp.

Amendment: SEC Form SC 13D/A filed by BriaCell Therapeutics Corp.

Amendment: SEC Form SC 13D/A filed by BriaCell Therapeutics Corp.

BriaCell Presents Clinical Efficacy Data Of Randomized Phase 2 Study Evaluating Bria-IMT In Patients With Advanced Metastatic Breast Cancer At ASCO 2024

Chat with this insight

Recent Analyst Ratings for $BCTX

$BCTX Financials

Live finance-specific insights

ImmunoPrecise Reports Financial Results and Recent Business Highlights for Full Fiscal Year 2023

$BCTX Leadership Updates

Live Leadership Updates

BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting

BriaCell Announces Rescheduling of its Annual General Meeting of Shareholders to February 5, 2025

BriaCell Announces Availability of Annual General Meeting Materials and Alternative Voting Procedures

$BCTX Press Releases

Fastest customizable press release news feed in the world

BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting

BriaCell Therapeutics Announces Closing of Public Offering

BriaCell Therapeutics Announces Pricing of Public Offering

$BCTX Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Lustig Marc bought $2,000,001 worth of shares (902,935 units at $2.21) (SEC Form 4)

$BCTX SEC Filings

BriaCell Therapeutics Corp. filed SEC Form 8-K: Other Events

BriaCell Therapeutics Corp. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

BriaCell Therapeutics Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits

$BCTX Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Lustig Marc bought $2,000,001 worth of shares (902,935 units at $2.21) (SEC Form 4)

SEC Form 4: Bondarenko Jamieson bought $128,240 worth of shares (28,000 units at $4.58), increasing direct ownership by 20% to 169,856 units

SEC Form 4 filed by Williams William V.

$BCTX Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

HC Wainwright & Co. initiated coverage on BriaCell Therapeutics with a new price target

$BCTX Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13D/A filed by BriaCell Therapeutics Corp.

Amendment: SEC Form SC 13D/A filed by BriaCell Therapeutics Corp.

Amendment: SEC Form SC 13D/A filed by BriaCell Therapeutics Corp.

Recent Analyst Ratings for
$BCTX

$BCTX
Financials

$BCTX
Leadership Updates

$BCTX
Press Releases

$BCTX
Insider Purchases

$BCTX
SEC Filings

$BCTX
Insider Trading

$BCTX
Analyst Ratings

$BCTX
Large Ownership Changes